
## William G Powderly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1345002/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	5.8	2,195
2	A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation. New England Journal of Medicine, 1992, 326, 845-851.	27.0	1,175
3	A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients. Clinical Infectious Diseases, 2003, 37, 634-643.	5.8	746
4	Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1997, 337, 15-21.	27.0	745
5	Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. New England Journal of Medicine, 2008, 358, 2095-2106.	27.0	667
6	Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis. New England Journal of Medicine, 1992, 326, 83-89.	27.0	643
7	Antifungal Susceptibility Survey of 2,000 Bloodstream <i>Candida</i> Isolates in the United States. Antimicrobial Agents and Chemotherapy, 2003, 47, 3149-3154.	3.2	493
8	A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection. New England Journal of Medicine, 1995, 333, 1534-1540.	27.0	482
9	Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLoS ONE, 2009, 4, e5575.	2.5	460
10	Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Aids, 2000, 14, F63-F67.	2.2	455
11	A Controlled Trial of Trimethoprim–Sulfamethoxazole or Aerosolized Pentamidine for Secondary Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1992, 327, 1842-1848.	27.0	365
12	A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1992, 326, 793-798.	27.0	362
13	A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 693-699.	27.0	341
14	Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 257-275.	2.1	338
15	A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 700-705.	27.0	333
16	Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. Annals of Internal Medicine, 2002, 137, 105.	3.9	304
17	Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 1011-1019.	2.1	288
18	Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected Individuals. Clinical Infectious Diseases, 2003, 36, 482-490.	5.8	286

#	Article	IF	CITATIONS
19	Nontuberculous Pyogenic Spinal Infection in Adults. Spine, 2006, 31, 2695-2700.	2.0	243
20	Amphotericin B-resistant yeast infection in severely immunocompromised patients. American Journal of Medicine, 1988, 84, 826-832.	1.5	238
21	Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. American Journal of Medicine, 1995, 98, 336-342.	1.5	237
22	Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. Aids, 2009, 23, 1109-1118.	2.2	223
23	Sex Differences in Nevirapine Rash. Clinical Infectious Diseases, 2001, 32, 124-129.	5.8	204
24	Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Science Advances, 2020, 6, .	10.3	204
25	Recovery of the Immune System With Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 1998, 280, 72.	7.4	196
26	Antiretroviral Activity of the Antiâ€CD4 Monoclonal Antibody TNXâ€355 in Patients Infected with HIV Type 1. Journal of Infectious Diseases, 2004, 189, 286-291.	4.0	194
27	Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management, 1997, 14, 7-14.	1.2	184
28	Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population. Clinical Infectious Diseases, 2007, 44, 726-734.	5.8	176
29	Pulmonary Cryptococcosis in Patients Without HIV Infection. Chest, 1999, 115, 734-740.	0.8	174
30	Measurement of Cryptococcal Antigen in Serum and Cerebrospinal Fluid: Value in the Management of AIDS-Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 1994, 18, 789-792.	5.8	171
31	Predictors of optimal virological response to potent antiretroviral therapy. Aids, 1999, 13, 1873-1880.	2.2	167
32	Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Individuals for Whom Interferonâ€Î± and Lamivudine Therapy Have Failed. Journal of Infectious Diseases, 2002, 186, 1844-1847.	4.0	160
33	Recommendations for Evaluation and Management of Bone Disease in HIV. Clinical Infectious Diseases, 2015, 60, 1242-1251. Treatment of Histoplasmosis With Fluconazole in Patients With Acquired Immunodeficiency	5.8	150
34	Syndromefn1fn1This study has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Contract Numbers: NO1-AI-15082 and NO1-AI-65296; the AIDS Clinical Trials Group and the Mycoses Study Group (Contract Numbers) Tj ETQq0 C	0 rgBT /C	overlock 10 Tf
35	Institutes of Health Genera. American Journal of Medicine, 1997, 103, 223-232. Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected Persons. Clinical Infectious Diseases, 2005, 41, 1045-1048.	5.8	139
36	Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated With	2.1	136

HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 426-431.

#	Article	IF	CITATIONS
37	Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLoS ONE, 2010, 5, e11416.	2.5	135
38	Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. Aids, 1999, 13, F23-F28.	2.2	134
39	A Randomized, Doubleâ€Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1998, 177, 48-56.	4.0	130
40	Insulin Resistance in HIV Protease Inhibitor–Associated Diabetes. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 209.	2.1	129
41	Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2004, 292, 180.	7.4	125
42	Resistance to amphotericin B associated with defective sterolΔ8→7isomerase in aCryptococcus neoformansstrain from an AIDS patient. FEMS Microbiology Letters, 1994, 122, 39-42.	1.8	120
43	Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. Journal of Applied Physiology, 2001, 90, 133-138.	2.5	111
44	Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. Aids, 2011, 25, 1405-1414.	2.2	105
45	Association of Upper Trunk and Visceral Adipose Tissue Volume With Insulin Resistance in Control and HIV-Infected Subjects in the FRAM Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 283-290.	2.1	104
46	Blood (1->3)-Â-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. Clinical Infectious Diseases, 2011, 53, 197-202.	5.8	104
47	Long-term Exposure to Lifelong Therapies. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, S28-S40.	2.1	102
48	The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. Journal of Clinical Investigation, 2004, 114, 206-213.	8.2	102
49	Switching Effective Antiretroviral Therapy: A Review. Clinical Infectious Diseases, 2002, 35, 1219-1230.	5.8	95
50	Refractory Mucosal Candidiasis in Advanced Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2000, 30, 749-756.	5.8	93
51	Therapy for Cryptococcal Meningitis in Patients with AIDS. Clinical Infectious Diseases, 1992, 14, S54-S59.	5.8	90
52	Molecular Epidemiology of Recurrent Oral Candidiasis in Human Immunodeficiency Virus-Positive Patients: Evidence for Two Patterns of Recurrence. Journal of Infectious Diseases, 1993, 168, 463-466.	4.0	87
53	USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: An Overview*. Clinical Infectious Diseases, 1995, 21, S12-S31.	5.8	84
54	Failure of Prophylactic Ganciclovir to Prevent Cytomegalovirus Disease in Recipients of Lung Transplants. Journal of Infectious Diseases, 1992, 165, 548-552.	4.0	83

#	Article	IF	CITATIONS
55	HIV Proteins Regulate Bone Marker Secretion and Transcription Factor Activity in Cultured Human Osteoblasts with Consequent Potential Implications for Osteoblast Function and Development. AIDS Research and Human Retroviruses, 2007, 23, 1521-1530.	1.1	82
56	Comparative Epidemiology and Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ Transplant Associated Cryptococcosis: A Population-Based Study. Clinical Infectious Diseases, 2018, 66, 608-611.	5.8	81
57	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. Aids, 2000, 14, 979-985.	2.2	78
58	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical Infectious Diseases, 2005, 41, 1473-1480.	5.8	72
59	Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. Lancet Infectious Diseases, The, 2019, 19, 1336-1344.	9.1	72
60	Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. Aids, 1992, 6, 81-84.	2.2	71
61	Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1998, 26, 556-565.	5.8	71
62	Has the Epidemiology of Nosocomial Candidemia Changed?. Infection Control and Hospital Epidemiology, 2004, 25, 628-633.	1.8	71
63	Serious Pseudomonas aeruginosa Infections in Patients Infected with Human Immunodeficiency Virus: A Case-Control Study. Clinical Infectious Diseases, 1994, 19, 417-422.	5.8	70
64	Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis. Clinical Infectious Diseases, 2005, 41, 1326-1332.	5.8	70
65	A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus–negative People in the United States. Clinical Infectious Diseases, 2020, 70, 252-261.	5.8	68
66	APOBEC3F and APOBEC3G mRNA Levels Do Not Correlate with Human Immunodeficiency Virus Type 1 Plasma Viremia or CD4 + T-Cell Count. Journal of Virology, 2006, 80, 2069-2072.	3.4	66
67	Prospects for Preventing Cryptococcosis in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1995, 21, S103-S107.	5.8	64
68	Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism: Clinical and Experimental, 1997, 46, 303-305.	3.4	64
69	Diagnosis and Treatment of Oropharyngeal Candidiasis in Patients Infected with HIV: A Critical Reassessment. AIDS Research and Human Retroviruses, 1999, 15, 1405-1412.	1.1	64
70	Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 39, 419-425.	5.8	64
71	A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults. Antiviral Therapy, 2003, 8, 279-287.	1.0	63
72	Clinical perspectives of emerging pathogens in bleeding disorders. Lancet, The, 2006, 367, 252-261.	13.7	60

#	Article	IF	CITATIONS
73	Resistant Candidiasis. AIDS Research and Human Retroviruses, 1994, 10, 925-929.	1.1	59
74	Itraconazole Maintenance Treatment for Histoplasmosis in AIDS: A Prospective, Multicenter Trial. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 100-107.	0.3	56
75	Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk. PLoS ONE, 2008, 3, e2021.	2.5	56
76	HIV Protease Inhibitors Selectively Induce Gene Expression Alterations Associated with Reduced Calcium Deposition in Primary Human Osteoblasts. AIDS Research and Human Retroviruses, 2007, 23, 243-250.	1.1	54
77	MSC-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2019, 74, 3056-3062.	3.0	54
78	Recent Advances in the Management of Cryptococcal Meningitis in Patients with AIDS. Clinical Infectious Diseases, 1996, 22, S119-S123.	5.8	53
79	Epidemiology of Cryptococcosis and Cryptococcal Meningitis in a Large Retrospective Cohort of Patients After Solid Organ Transplantation. Open Forum Infectious Diseases, 2017, 4, ofx004.	0.9	53
80	Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4+T Cell Decline in Human Immunodeficiency Virus–Infected Patients: Implications for Intermittent Therapeutic Strategies. Journal of Infectious Diseases, 2002, 186, 851-854.	4.0	50
81	Integrase inhibitors in the treatment of HIV-1 infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 2485-2488.	3.0	49
82	Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 501-515.	4.7	49
83	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open, 2016, 6, e009586.	1.9	49
84	Invasive Fungal Infections Secondary to Traumatic Injury. International Journal of Infectious Diseases, 2017, 62, 102-111.	3.3	49
85	Patterns of Opportunistic Infections in Patients with HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 38-45.	0.3	48
86	Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. American Journal of Medicine, 1993, 95, 273-278.	1.5	47
87	Evaluation of the Virological and Metabolic Effects of Switching Protease Inhibitor Combination Antiretroviral Therapy to Nevirapine-Based Therapy for the Treatment of HIV Infection. AIDS Research and Human Retroviruses, 2004, 20, 589-594.	1.1	47
88	Risk Factors for Dideoxynucleoside-Induced Toxic Neuropathy in Patients with the Human Immunodeficiency Virus Infection. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 169-174.	0.3	46
89	End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis. Open Forum Infectious Diseases, 2016, 3, ofv197.	0.9	45
90	Review: Hepatic Steatosis and HIV Infection. AIDS Patient Care and STDs, 2005, 19, 356-365.	2.5	44

#	Article	IF	CITATIONS
91	Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV. Clinical Infectious Diseases, 2016, 64, ciw786.	5.8	44
92	HIV Type 1 Alters Mesenchymal Stem Cell Differentiation Potential and Cell Phenotype <i>ex Vivo</i> . AIDS Research and Human Retroviruses, 2011, 27, 187-199.	1.1	43
93	Genetic analysis implicates resistin in HIV lipodystrophy. Aids, 2008, 22, 1561-1568.	2.2	42
94	Osteoporosis and Bone Health in HIV. Current HIV/AIDS Reports, 2012, 9, 218-222.	3.1	42
95	Cryptococcosis Today: It Is Not All About HIV Infection. Current Clinical Microbiology Reports, 2017, 4, 88-95.	3.4	41
96	Increased plasma Gln and Leu Raand inappropriately low muscle protein synthesis rate in AIDS wasting. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E577-E583.	3.5	40
97	A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma. Journal of Acquired Immune Deficiency Syndromes, 1996, 11, 379-384.	0.3	39
98	Clinical Perspective Oropharyngeal Candidiasis in Patients with HIV: Suggested Guidelines for Therapy. AIDS Research and Human Retroviruses, 1999, 15, 1619-1623.	1.1	38
99	HIV and its relationship to insulin resistance and lipid abnormalities. Translational Research, 2017, 183, 41-56.	5.0	37
100	Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskeletal Disorders, 2008, 9, 33.	1.9	36
101	A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 140-148.	2.1	35
102	Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. Aids, 2013, 27, 967-972.	2.2	35
103	Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants. Journal of Hepatology, 2014, 60, 508-514.	3.7	35
104	In Vivo Virulence ofCandida albicansIsolates Causing Mucosal Infections in People Infected with the Human Immunodeficiency Virus. Journal of Infectious Diseases, 2000, 182, 955-959.	4.0	34
105	The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date. Clinical Infectious Diseases, 2004, 39, 98-106.	5.8	34
106	Whole-Body Proteolysis Rate Is Elevated in HIV-Associated Insulin Resistance. Diabetes, 2006, 55, 2849-2855.	0.6	34
107	Presentation and Mortality of Cryptococcal Infection Varies by Predisposing Illness: A Retrospective Cohort Study. American Journal of Medicine, 2019, 132, 977-983.e1.	1.5	33
108	Understanding Drivers of Coronavirus Disease 2019 (COVID-19) Racial Disparities: A Population-Level Analysis of COVID-19 Testing Among Black and White Populations. Clinical Infectious Diseases, 2021, 73, e2921-e2931.	5.8	33

#	Article	IF	CITATIONS
109	Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism: Clinical and Experimental, 2005, 54, 561-567.	3.4	32
110	Reducing plasma HIV RNA improves muscle amino acid metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E278-E284.	3.5	31
111	Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E812-E819.	3.5	31
112	Cryptococcal meningitis in HIV-infected patients. Current Infectious Disease Reports, 2000, 2, 352-357.	3.0	30
113	Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Aids, 2000, 14, 845-852.	2.2	30
114	Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, ofx242.	0.9	30
115	Understanding mechanisms to promote successful aging in persons living with HIV. International Journal of Infectious Diseases, 2018, 66, 56-64.	3.3	30
116	Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. Aids, 2008, 22, 849-856.	2.2	29
117	Designing for Accelerated Translation (DART) of emerging innovations in health. Journal of Clinical and Translational Science, 2019, 3, 53-58.	0.6	27
118	Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits. Clinical Infectious Diseases, 2004, 38, S109-S113.	5.8	26
119	A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/l. Aids, 2001, 15, 1509-1515.	2.2	25
120	Nelfinavir mesylate. Expert Opinion on Pharmacotherapy, 2000, 1, 1429-1440.	1.8	24
121	Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. PLoS ONE, 2017, 12, e0173057.	2.5	24
122	Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 75, 2060-2065.	5.8	24
123	Symptomatic Cytomegalovirus Infection in Renal Transplant Recipients Given Either Minnesota Antilymphoblast Globulin (MALG) or OKT3 for Rejection Prophylaxis. American Journal of Kidney Diseases, 1993, 21, 196-201.	1.9	23
124	Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. Antiviral Research, 2000, 45, 47-58.	4.1	23
125	Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E899-E905.	3.5	23
126	Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. Aids, 2006, 20, 2115-2116.	2.2	23

#	Article	IF	CITATIONS
127	Missed Opportunities to Prescribe HIV Pre-Exposure Prophylaxis by Primary Care Providers in Saint Louis, Missouri. LGBT Health, 2018, 5, 250-256.	3.4	23
128	EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. Open Forum Infectious Diseases, 2018, 5, ofy299.	0.9	23
129	Cryptococcal meningitis in AIDS. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 139-150.	1.8	23
130	HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. Antiviral Research, 2007, 74, 72-76.	4.1	21
131	Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. Aids, 2017, 31, 71-79.	2.2	20
132	Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort. Clinical Infectious Diseases, 2021, 73, e3727-e3732.	5.8	20
133	A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. Aids, 1998, 12, 2439-2446.	2.2	19
134	Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: The BAN study. Journal of Clinical Virology, 2012, 54, 318-320.	3.1	19
135	Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 396-399.	2.1	19
136	Alterations in Spliced and Unspliced HIV-1-Specific RNA Detection in Peripheral Blood Mononuclear Cells of Individuals with Varying CD4-Positive Lymphocyte Counts. AIDS Research and Human Retroviruses, 1993, 9, 1257-1263.	1.1	18
137	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. Aids, 2001, 15, 591-599.	2.2	18
138	Risk factors predicting Candida infective endocarditis in patients with candidemia. Medical Mycology, 2020, 58, 593-599.	0.7	18
139	Renal glomerulopathies associated with Hodgkin's disease. Cancer, 1985, 56, 874-875.	4.1	17
140	Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV Clinical Trials, 2010, 11, 248-259.	2.0	17
141	Elevated Lactate Levels in Hospitalized Persons with HIV Infection. AIDS Research and Human Retroviruses, 2001, 17, 195-201.	1.1	16
142	Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria. Mycoses, 2019, 62, 554-561.	4.0	16
143	Response to â€~Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy' by Drs Weil and Lenhard. Aids, 2000, 14, 2417.	2.2	16
144	Sequence Heterogeneity of Nef Transcripts in HIV-1-Infected Subjects at Different Stages of Disease. Virology, 1996, 223, 245-250.	2.4	15

#	Article	IF	CITATIONS
145	Molecular Epidemiology of Mucosal Candidiasis in HIV-Positive Women. AIDS Research and Human Retroviruses, 1997, 13, 485-491.	1.1	15
146	Cryptococcosis. Advances in Pharmacology, 1996, 37, 215-251.	2.0	14
147	Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. Journal of Clinical Gastroenterology, 2017, 51, 70-76.	2.2	14
148	A comparison of presentations and outcomes of histoplasmosis across patients with varying immune status. Medical Mycology, 2021, 59, 624-633.	0.7	14
149	RISKS OF HIV INFECTION IN THE HEALTH CARE SETTING. Annual Review of Medicine, 1995, 46, 203-211.	12.2	13
150	Editorial Commentary: Centers for Disease Control and Prevention Revised Guidelines for Human Immunodeficiency Virus (HIV) Counseling, Testing, and Referral: Targeting HIV Specialists. Clinical Infectious Diseases, 2003, 37, 813-819.	5.8	13
151	A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. HIV Clinical Trials, 2010, 11, 80-99.	2.0	13
152	Benefits of Direct-Acting Antivirals for Hepatitis C. Annals of Internal Medicine, 2017, 167, 812.	3.9	13
153	Sorting Through Confusing Messages: The Art of HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S3-S9.	2.1	12
154	Mortality After Cryptococcal Infection in the Modern Antiretroviral Therapy Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 81-87.	2.1	12
155	Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV. Journal of Clinical Microbiology, 2020, 58, .	3.9	12
156	Association of Adverse Events With Antibiotic Treatment for Urinary Tract Infection. Clinical Infectious Diseases, 2022, 74, 1408-1418.	5.8	12
157	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathogens, 2022, 18, e1010547.	4.7	12
158	The interaction of opportunistic infections and HIV replication. Aids, 1999, 13, 1603-1006.	2.2	11
159	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases, 2017, 65, 1773-1775.	5.8	11
160	Creation and Assessment of a Clinical Predictive Calculator and Mortality Associated With Candida krusei Bloodstream Infections. Open Forum Infectious Diseases, 2018, 5, ofx253.	0.9	11
161	Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: A cohort study. EClinicalMedicine, 2020, 27, 100563.	7.1	11
162	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. Journal of Clinical and Translational Science, 2021, 5, e96.	0.6	11

#	Article	IF	CITATIONS
163	Phase I Study of Atevirdine Mesylate (U-87201E) Monotherapy in HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 135-144.	0.3	10
164	Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Current Opinion in HIV and AIDS, 2007, 2, 318-323.	3.8	10
165	AIDS-Defining Illnesses at Initial Diagnosis of HIV in a Large Guatemalan Cohort. Open Forum Infectious Diseases, 2017, 4, ofx249.	0.9	10
166	Treatment of acute cryptococcal disease. Expert Opinion on Pharmacotherapy, 2001, 2, 1259-1268.	1.8	9
167	Developing a Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Therapeutic Research Agenda for Resourceâ€Limited Countries: A Consensus Statement. Clinical Infectious Diseases, 2003, 37, S4-S12.	5.8	9
168	Current advances in pharmacovigilance in the USA and Europe. Current Opinion in HIV and AIDS, 2012, 7, 292-298.	3.8	9
169	Invasive Fungal Infections: Cryptococcosis. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 249-257.	2.1	8
170	Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. Aids, 2005, 19, 1439-1440.	2.2	8
171	Vitamin D and Calcium Abnormalities in the HIV-Infected Population. Endocrinology and Metabolism Clinics of North America, 2014, 43, 743-767.	3.2	8
172	Late Presentation and Missed Opportunities for HIV Diagnosis in Guatemala. AIDS and Behavior, 2019, 23, 920-928.	2.7	8
173	GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. The Open Virology Journal, 2011, 5, 109-113.	1.8	8
174	SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County. Annals of Epidemiology, 2022, 71, 31-37.	1.9	8
175	Editorial Commentary:Dosing Amphotericin B in Cryptococcal Meningitis. Clinical Infectious Diseases, 2008, 47, 131-132.	5.8	7
176	Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. IDCases, 2016, 6, 79-82.	0.9	7
177	Comfort Discussing HIV Pre-exposure Prophylaxis With Patients Among Physicians in an Urban Emergency Department. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e49-e52.	2.1	7
178	Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. Journal of Clinical Virology, 2004, 31, 198-203.	3.1	6
179	Documented Prevalence of HIV Type 1 Antiretroviral Transmitted Drug Resistance in Ireland from 2004 to 2008. AIDS Research and Human Retroviruses, 2012, 28, 276-281.	1.1	6
180	Outcomes Associated With Social Distancing Policies in St Louis, Missouri, During the Early Phase of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2123374.	5.9	6

#	Article	IF	CITATIONS
181	HIV: primary and secondary prophylaxis for opportunistic infections. Clinical Evidence, 2010, 2010, .	0.2	6
182	PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS. Infectious Disease Clinics of North America, 2000, 14, 929-944.	5.1	5
183	Cryptococcal infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 159-167.	1.8	5
184	Is There a Higher Risk of CNS Adverse Events for PI Monotherapy Versus Triple Therapy? A Review of Results From Randomized Clinical Trials. HIV Clinical Trials, 2014, 15, 79-86.	2.0	5
185	Sex Venue-Based Network Analysis to Identify HIV Prevention Dissemination Targets for Men Who Have Sex with Men. LGBT Health, 2018, 5, 78-85.	3.4	5
186	Long-Term Mortality after Histoplasma Infection in People with HIV. Journal of Fungi (Basel,) Tj ETQqO 0 0 rgBT /	Overlock 1	0 tf 50 542 <sup>-</sup>
187	TREATMENT OF INFECTION DUE TO MYCOBACTERIUM AVIUM COMPLEX. Pediatric Infectious Disease Journal, 1999, 18, 468-469.	2.0	5
188	Prophylaxis for HIV-Related Infections: A Work in Progress. Annals of Internal Medicine, 1996, 124, 342.	3.9	4
189	Immune reconstitution and the consequences for opportunistic infection treatment and prevention. Current Infectious Disease Reports, 1999, 1, 99-104.	3.0	4
190	Limitations of Current HIV Therapies. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, S7???S12.	2.1	4
191	Proposed U.S. Funding Cuts Threaten Progress on Antimicrobial Resistance. Annals of Internal Medicine, 2017, 167, 738.	3.9	4
192	Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSA. Journal of Infectious Diseases, 2020, 222, S554-S559.	4.0	4
193	Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease. Mycoses, 2021, 64, 174-180.	4.0	4
194	Rifabutin Induced Vitritis in AIDS Patients. Ocular Immunology and Inflammation, 1996, 4, 219-224.	1.8	3
195	OVERVIEW. Aids, 2001, 15, S159-S160.	2.2	3
196	Human Immunodeficiency Virus Type 1 in Ireland: Phylogenetic Evidence for Risk Group-Specific Subepidemics. AIDS Research and Human Retroviruses, 2012, 28, 1073-1081.	1.1	3
197	Comments on cochrane review on directâ€acting antivirals for hepatitis C. Hepatology, 2017, 66, 1016-1019.	7.3	3
198	Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and Industry. International Journal of Radiation Oncology Biology Physics, 2020, 107, 867-872.	0.8	3

0

#	Article	IF	CITATIONS
199	Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment. Current HIV Research, 2009, 7, 508-518.	0.5	2
200	Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. Pharmacoepidemiology and Drug Safety, 2021, 30, 1360-1370.	1.9	2
201	Clinical predictive models of invasive Candida infection: A systematic literature review. Medical Mycology, 2021, 59, 1053-1067.	0.7	2
202	Opportunistic infections. , 2010, , 964-974.		2
203	Resistant Candidiasis. AIDS Patient Care and STDs, 1995, 9, 32-36.	0.1	1
204	Effect of Opportunistic Illness on Risk of Death in HIV Disease. JAMA - Journal of the American Medical Association, 1998, 279, 1500.	7.4	1
205	Osteoporosis in HIV-Infected Patients. Clinical Reviews in Bone and Mineral Metabolism, 2004, 2, 167-174.	0.8	1
206	Candida in HIV infection. , 2012, , 359-367.		1
207	Antiretroviral therapy in primary HIV infection. Journal of Comparative Effectiveness Research, 2013, 2, 227-229.	1.4	1
208	Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS. Aids, 2013, 27, 2967-2968.	2.2	1
209	Infectious disease consultation for candidaemia – Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 165-166.	9.1	1
210	Gender-Specific Issues in Fungal Infections. , 2004, , 910-922.		1
211	Opportunistic infections. Current Opinion in Infectious Diseases, 1996, 9, 23-27.	3.1	0
212	Cytomegalovirus Retinitis Treatment. JAMA - Journal of the American Medical Association, 1997, 278, 1287.	7.4	0
213	Clinical: Overview. Aids, 2002, 16, S133-S134.	2.2	0
214	Management of antiretroviral drug toxicity. Current Opinion in HIV and AIDS, 2006, 1, 430-436.	3.8	0
215	Cryptococcus. , 0, , 1205-1210.		0

#	Article	IF	CITATIONS
217	Management of late presentation in HIV: what the data tell us. HIV Therapy, 2009, 3, 423-426.	0.6	0
218	When to start antiretroviral therapy: asking the right question. Future Virology, 2011, 6, 401-403.	1.8	0
219	HIV-associated osteoporosis in Ireland: prevalence and risk factors. Future Virology, 2012, 7, 791-799.	1.8	Ο
220	Cryptococcus. , 0, , 1128-1133.		0
221	Early Human Immunodeficiency Virus (HIV) Diagnosis in Guatemala: An Elusive Opportunity. Open Forum Infectious Diseases, 2016, 3, .	0.9	Ο
222	The Value of the Serum Aspergillus Galactomannan (GM) to Diagnose Invasive Aspergillosis (IA) and Invasive Fungal Infections (IFI) as Defined by European Organization of Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) in Recipients of Hematopoietic Stem Cell Transplants (HSCT) Open Forum Infectious Diseases, 2016, 3, .	0.9	0
223	Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases, 2017, 4, S75-S75.	0.9	Ο
224	Conflicts of Interest Reported in an Abbreviated Time Frame. JAMA Internal Medicine, 2017, 177, 1059.	5.1	0
225	Issues in the Aging HIV-Positive Patient. , 2017, , 927-930.e1.		Ο
226	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. Antiviral Therapy, 2017, 23, 379-382.	1.0	0
227	376. Predictive Model for Fluconazole Resistance in Patient With Candida Bloodstream Infection. Open Forum Infectious Diseases, 2018, 5, S146-S146.	0.9	Ο
228	556. Factors Associated with Integrase Strand Transfer Inhibitor Use Between 2008 and 2015. Open Forum Infectious Diseases, 2018, 5, S206-S207.	0.9	0
229	394. Outcomes in Patients With Disseminated Noncentral Nervous System Cryptococcus. Open Forum Infectious Diseases, 2018, 5, S152-S152.	0.9	Ο
230	395. Missed Opportunities for Diagnosis of Cryptococcal Disease in Patients From Florida. Open Forum Infectious Diseases, 2018, 5, S152-S152.	0.9	0
231	397. Long-Term Mortality of HIV Patients Following Cryptococcal Infection. Open Forum Infectious Diseases, 2018, 5, S153-S153.	0.9	Ο
232	1030. Risk Predictive Model for Candida Endocarditis in Patients with Candidemia: A 12-year Experience in a Single Tertiary Care Hospital. Open Forum Infectious Diseases, 2018, 5, S307-S307.	0.9	0
233	Brief Report: Aging Attenuates the Association Between Coronary Artery Calcification and Bone Loss Among HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 46-50.	2.1	0
234	Adopting locally the lessons learned globally: a call to action for academic medical centres in the USA. BMJ Global Health, 2020, 5, e002238.	4.7	0

#	Article	IF	CITATIONS
235	COVID-19 and Outpatient Parenteral Antimicrobial Therapy. Annals of Internal Medicine, 2021, 174, 142.	3.9	0
236	Candida in HIV Infection. , 2008, , 365-373.		0
237	Authors' Reply: Campylobacter spp. Bacteremia in AIDS Patients. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 94.	0.3	0
238	Opportunities to improve clinical care in HIV disease: designing an effective antiretroviral drug regimen for your patient. Introduction. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33 Suppl 1, S5-6.	2.1	0